MoradinejadMHZiaeeV. The incidence of macrophage activation syndrome in children with rheumatic disorders. Minerva Pediatr2011; 63: 459–466.
2.
TrottestamHHorneAAricòM. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH 94 treatment protocol. Blood2011; 118: 4577–4584.
3.
LambotteOKhellafMHarmoucheH. Characteristics and long-term outcome of 15 of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. Medicine (Baltimore)2006; 85: 169–182.
4.
MahlaouiNOuachée-ChardinMde Saint BasileG. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: A single center retrospective report of 38 patients. Pediatrics2007; 120: 622–628.
5.
RajajeeSAshokIManwaniNRajkumarJGowrishankarKSubbiahE. Profile of hemophagocytic lymphohistiocytosis; efficacy of intravenous immunoglobulin therapy. Indian J Pediatr2014; 81: 1337–1341.
6.
MarshRAAllenCEMcClainKL. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer2013; 60: 102–109.
7.
FismanDN. Hemophagocytic syndrome and infection. Emerg Infect Dis2000; 6: 601–608.
